Elkedonia

About Elkedonia

Elkedonia SAS operates as a Franco-Belgian biotechnology company focused on creating a new class of treatments for major depressive disorder (MDD) and other neuropsychiatric conditions. The firm was established in 2025, launching with an oversubscribed seed funding round of €11.25 million. This initial financing was co-led by Kurma Partners, WE Life Sciences, and the French Tech Seed Fund, with additional participation from Argobio, Angelini Ventures, and others.

The company was founded by the biotech startup studio Argobio, alongside CEO Dr. Delphine Charvin and co-founder Mélanie Rouillier. Dr. Charvin is a scientist and entrepreneur with 15 years of experience in drug development and has held leadership roles in various biotechs, contributing to fundraising efforts totaling over €150 million. The scientific foundation of Elkedonia is built upon the translational research of Dr. Jocelyne Caboche, Director of Research at the National Center for Scientific Research (CNRS) at Sorbonne University. Dr. Caboche's work identified the intracellular protein Elk1 as a critical modulator of brain circuits related to reward and neuroplasticity, which are disrupted in conditions like depression and PTSD.

Elkedonia's business model is centered on the research and development of proprietary drug candidates, with the ultimate goal of bringing them to clinical trials and eventual commercialization. Its core strategy involves identifying small-molecule inhibitors of Elk1. Proceeds from its seed round are allocated to optimizing these small molecules and developing companion biomarkers for a precision medicine approach. The company's business activities are preclinical, with plans to select a lead compound and commence clinical development around 2029.

The company is developing first-in-class neuroplastogens that aim to restore the brain's neuroplasticity. Unlike existing treatments such as ketamine or psychedelics that act on synapses, Elkedonia's molecules target the intracellular Elk1 protein. This specific mechanism is designed to provide rapid therapeutic effects without inducing side effects like sedation, dependency, or hallucinations. The market Elkedonia addresses is significant, targeting the approximately 300 million people globally affected by MDD, particularly the one-third of patients who are resistant to current treatments. The company's approach allows it to target a broad patient population, including adolescents and those with comorbidities.